South Wales, Sept. 17 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "HAYQURO" on Aug. 18. The details about the trademark application no. UK00004250755 published in the journal no. 2025/035 (Aug. 29).
With D Young & Co LLP as representative, Intellia Therapeutics, Inc. filed the trademark application for the below mentioned good(s)/service(s).
Class 5 : Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for use with protein disorders and genetic diseases; Intravenous injectable gene therapy preparations for treating and managing swelling attacks; Therapeutic agents in the nature of CRISPR/Cas9 protein with guide RNAs targeting the KLKB1 gene to reduce production of plasma prekallikrein and control bradykinin generation.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004250755
Disclaimer: Curated by HT Syndication.
